Biotech stocks including GI Innovation and D&D Pharmatech surge together
22On the day, GI Innovation surged after ASCO abstracts were released, while23% and D&D Pharmatech rose on expectations for clinical data at the European Association for the Study of the Liver congress by14%. Ingenia Therapeutics received preliminary approval for its listing review, while Lunit will present research findings at ASCO2026.
Get free 디앤디파마텍 email updates.
Bullstory sends one daily email when new analysis or important company news is available.
22On the day, major biotech stocks rose across the KOSPI and KOSDAQ. GI Innovation's share price rose23%. D&D Pharmatech's share price rose on expectations for potential clinical results at the European Association for the Study of the Liver congress (EASL)14%.
GI Innovation said it reported an objective response rate (ORR) of40%. The company said its clinical data had drawn attention following the release of its ASCO abstract. The news appears to have affected investor sentiment.
D&D Pharmatech said expectations for clinical results had risen ahead of its conference presentation. The company disclosed specific figures and the presentation schedule. Investor interest translated into trading.
Ingenia Therapeutics has received preliminary approval for listing review. The company, a Korean-founded biotechnology firm based in the United States, is proceeding with its listing process. Passing the preliminary listing review means it can move on to the next stage.
Lunit will present research findings on AI-based biomarker analysis at ASCO 2026The company said it plans to disclose its research findings at the conference. The presentation is drawing attention from both a technology and commercialization perspective.
Solux announced that it is pursuing a change of corporate name to Ariwon and shifting its focus to the bio-platform business. The company said it would step up its business restructuring alongside the name change. It said that related disclosures and follow-up plans would follow.